World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
61212
World Ranking
8115
National Ranking
112

Overview

Jean-Yves Douillard is affiliated with the European Society for Medical Oncology in Switzerland. The primary field of study for their research is medicine, with a focus on oncology, pulmonary and respiratory medicine, economics and econometrics, public health, environmental and occupational health, and radiology, nuclear medicine and imaging.

The scientist's work covers several topics including:

  • Lung cancer diagnosis and treatment
  • Health systems, economic evaluations, quality of life
  • COVID-19 and healthcare impacts
  • Economic and financial impacts of cancer
  • Lung cancer treatments and mutations
  • Gastric cancer management and outcomes
  • Global cancer incidence and screening

Jean-Yves Douillard has contributed to various research papers, among which are:

  • "Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus" (2020), published in Annals of Oncology
  • "Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)" (2021), published in ESMO Open
  • "Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS" (2020), published in Annals of Oncology
  • "Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer" (2020), published in Annals of Oncology
  • "ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer" (2020), published in ESMO Open

The frequent co-authors associated with Jean-Yves Douillard's research include:

  • George Pentheroudakis
  • Solange Peters
  • Giuseppe Curigliano
  • Josep Tabernero
  • Andrés Cervantes

The scientist's research has been published mainly in the following venues:

  • ESMO Open
  • Annals of Oncology
  • JNCI Journal of the National Cancer Institute
  • JCO Global Oncology
  • Clinical Cancer Research

Best Publications

  • Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

    J Y Douillard;D Cunningham;Arnaud Roth;M Navarro

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Jean Pierre Pignon;Hélène Tribodet;Giorgio V. Scagliotti;Jean Yves Douillard

  • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

    Jean Yves Douillard;Kelly S. Oliner;Salvatore Siena;Josep Tabernero

  • Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]) : a randomised controlled trial

    Jean Yves Douillard;Rafael Rosell;Mario De Lena;Francesco Carpagnano

  • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

    Edward S. Kim;Vera Hirsh;Tony Mok;Mark A. Socinski

  • Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

    Jean Yves Douillard;Salvatore Siena;James Cassidy;Josep Tabernero

  • Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

    Ghassan K. Abou-Alfa;Lawrence Schwartz;Sergio Ricci;Dino Amadori

  • Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

    T Le Chevalier;D Brisgand;J Y Douillard;J L Pujol

  • Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

    Sylvie Negrier;Bernard Escudier;Christine Lasset;Jean-Yves Douillard

  • Radiotherapy Alone Versus Combined Chemotherapy and Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a Randomized Trial in 353 Patients

    T Le Chevalier;R Arriagada;E Quoix;P Ruffie

  • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

    Martin Reck;Rolf Kaiser;Anders Mellemgaard;Jean-Yves Douillard

  • Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.

    F. Mosele;J. Remon;J. Mateo;C. B. Westphalen

  • Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

    D. Arnold;B. Lueza;J.-Y. Douillard;M. Peeters

  • ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

    C. Luchini;F. Bibeau;M.J.L. Ligtenberg;N. Singh

  • Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

    Jean Yves Douillard;Frances A. Shepherd;Vera Hirsh;Tony Mok

  • Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

    Jean Yves Douillard;S. Siena;J. Cassidy;J. Tabernero

  • Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients

    C. Louvet;T. André;J.M. Tigaud;E. Gamelin

  • ESMO-Magnitude of Clinical Benefit Scale version 1.1

    N.I. Cherny;U. Dafni;J. Bogaerts;N.J. Latino

Frequent Co-Authors

Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Silvia Novello
Silvia Novello University of Turin
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Salvatore Siena
Salvatore Siena University of Milan
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Lesley Seymour
Lesley Seymour Queen's University
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Marc Peeters
Marc Peeters University of Antwerp
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While studying Medicine in the USA typically means pursuing a traditional MD or DO, there are many alternative online degrees and career pathways that can complement or expand your expertise in healthcare. For those interested in healthcare administration, a cahme accredited online mha programs list helps future leaders find reputable programs that meet industry standards for quality.

Nursing professionals might consider advancing their careers with a Bachelor of Science in Nursing. Some rn bsn online programs no clinicals allow registered nurses to complete their bachelor’s degree entirely online, with no clinical requirements—ideal for working nurses needing flexibility.

For nurses seeking the highest clinical leadership roles, accelerated dnp programs enable faster paths to a Doctor of Nursing Practice. Additionally, students can explore dnp programs designed for streamlined, efficient study, making advanced nursing education more accessible than ever.

Best Scientists Citing Jean-Yves Douillard

Trending Scientists

Recently Published Articles